LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Akcijų sąrašas・Pfizer

Pfizer

Uždarymo kaina

SektoriusSveikatos priežiūra

25.9 0.04

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

25.9

Max

Pagrindiniai rodikliai
By Trading Economics
Pajamos	4.3B 2.7B
Pardavimai	-3.1B 14B
P/E Sektoriaus vid.	19.336 49.701
Pelnas, tenkantis vienai akcijai	0.75
Dividendų pajamingumas	6.79
Pelno marža	18.656
Darbuotojai	75,000
EBITDA	4.5B 5.2B

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	+12.63% upside

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	6.79% 2.39%
Kitas uždarbis	2026-08-04
Kitas dividendų mokėjimo data	2026-06-12
Kita Ex Dividend data	2026-07-24

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-5.2B 144B
Ankstesnė atidarymo kaina	25.86
Ankstesnė uždarymo kaina	25.9

Naujienos nuotaikos

By Acuity

33%

67%

91 / 345 reitingas Healthcare

Pfizer Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-05 11:31; UTC

Uždarbis

Pfizer 1Q Revenue Rises But Profit Falls Amid Boosted R&D Spending

2026-05-05 18:12; UTC

Uždarbis

BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

2026-05-05 13:54; UTC

Uždarbis

BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

2026-05-05 12:35; UTC

Uždarbis

Pfizer Posts Better-Than-Expected Revenue, Profit -- WSJ

2026-05-05 11:06; UTC

Uždarbis

Pfizer Stock Edges Higher as Earnings and Revenue Beat Estimates -- Barrons.com

2026-05-05 10:47; UTC

Uždarbis

Pfizer: Current Financial Guidance Doesn't Anticipate Any Stock Buybacks in 2026 >PFE

2026-05-05 10:47; UTC

Uždarbis

Pfizer Still Sees 2026 Adjusted R&D Expenses $10.5B-$11.5B >PFE

2026-05-05 10:46; UTC

Uždarbis

Pfizer 1Q Revenue of Launched, Acquired Products Rose 22% Operationally >PFE

2026-05-05 10:46; UTC

Uždarbis

Pfizer 1Q Revenue Rose 7% Operationally Excluding Contributions From Comirnaty, Paxlovid >PFE

2026-05-05 10:45; UTC

Uždarbis

Pfizer Reaffirms 2026 Guidance >PFE

2026-05-05 10:45; UTC

Uždarbis

Pfizer Sees FY Rev $59.5B-$62.5B >PFE

2026-05-05 10:45; UTC

Uždarbis

Pfizer Sees FY Adj EPS $2.80-Adj EPS $3.00 >PFE

2026-05-05 10:45; UTC

Uždarbis

Pfizer 1Q Rev $14.5B >PFE

2026-05-05 10:45; UTC

Uždarbis

Pfizer 1Q EPS 47c >PFE

2026-05-05 10:45; UTC

Uždarbis

Pfizer 1Q Net $2.69B >PFE

2026-05-05 10:45; UTC

Uždarbis

Pfizer 1Q Adj EPS 75c >PFE

2026-05-05 10:36; UTC

Karštos akcijos

Stocks to Watch: Palantir, HSBC, Intel, AMD -- WSJ

2026-04-23 21:48; UTC

Įsigijimai, susijungimai, perėmimai

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

2026-04-01 20:07; UTC

Įsigijimai, susijungimai, perėmimai

Why 2026 Is Biotech's Comeback Year -- Barrons.com

2026-03-11 11:02; UTC

Rinkos pokalbiai

Sanofi, Regeneron's Eczema Drug Might Face Competition From Pfizer -- Market Talk

2026-03-10 12:50; UTC

Uždarbis

BioNTech Stock Plunges 17% After Earnings. Why the Drugmaker Faces a Perfect Storm. -- Barrons.com

2026-03-10 11:18; UTC

Uždarbis

BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock. -- Barrons.com

2026-03-09 09:43; UTC

Karštos akcijos

Stocks to Watch Monday: Lamb Weston, Carnival, Pfizer -- WSJ

2026-02-10 21:51; UTC

Uždarbis

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

2026-02-10 21:17; UTC

Uždarbis

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

2026-02-03 21:36; UTC

Uždarbis

These Stocks Are Today's Movers: Palantir, Pfizer, AMD, PayPal, Novo Nordisk, PepsiCo, Merck, and More -- Barrons.com

2026-02-03 19:56; UTC

Uždarbis

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

2026-02-03 19:46; UTC

Uždarbis

These Stocks Are Today's Movers: Palantir, Pfizer, AMD, PayPal, Novo Nordisk, PepsiCo, Merck, and More -- Barrons.com

2026-02-03 17:35; UTC

Uždarbis

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

2026-02-03 17:30; UTC

Uždarbis

These Stocks Are Today's Movers: Palantir, PayPal, Novo Nordisk, Pfizer, Merck, AMD, Gartner, and More -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Pfizer Prognozė

Kainos tikslas

By TipRanks

12.63% į viršų

12 mėnesių prognozė

Vidutinis 29.17 USD 12.63%

Aukščiausias 36 USD

Žemiausias 25 USD

Remiantis 22 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Pfizer kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

22 ratings

Pirkti

Laikyti

Parduoti

Remiantis 22 analitikų, pateikusių Pfizer akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

91 / 345 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.